Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 695.46

+2.0%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (2753)	10/10/2019 4:44:07 PM
From: Miljenko Zuanic	of 3557

I still do not believe that Eylea will lose significant (that will be hard to substitute by pipeline) amount of the WW-(US/EU)-sale due to new entrants (Novartis, Roche,.. ). It is still too early to figure out GT marketplace and how will market evolve. AMD/DME has still room to growth (US and EU)...Lucentis may suffer greatly than Eylea. IF CMS/part-B develop unfavorably, all cards are off. On bio-similar front, manufacturing/know-how will protect until 2037, at least. IMO

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next